<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364268">
  <stage>Registered</stage>
  <submitdate>16/05/2013</submitdate>
  <approvaldate>24/05/2013</approvaldate>
  <actrnumber>ACTRN12613000584730</actrnumber>
  <trial_identification>
    <studytitle>Effects of a traditional Persian medicine syrup (Jollab) on Functional Dyspepsia patients</studytitle>
    <scientifictitle>Survey on a traditional Iranian medicine syrup (Jollab) in relieving gastrointestinal symptoms in Functional Dyspepsia (FD) patients: a randomized double-blind placebo-controlled clinical trial</scientifictitle>
    <utrn>U1111-1143-1766</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Functional Dyspepsia </healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A traditional Persian medicine syrup named Jollab, is administered orally 3 times daily, 45 milliliters totally, during 4 weeks. this syrup is a combination of distilled water, Rose water, Saffron and Sugar as mentioned in Avicenna's book (Al-Qanoon fil-teb). As the active agents have synergistic effect, there isn't way to specify the active ingredients amount.  
In order to monitor adherence, patient should check a form and render this form in follow-up meetings.      </interventions>
    <comparator>A combination of distilled water, Standard dye material and 5% Rose water</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relief in Gastrointestinal symptoms in functional dyspepsia patients assessed by Leeds Questionaire </outcome>
      <timepoint>0- Baseline
1- At two weeks after the beginning of trial
2- At one month after the beginning of trial
3- At two months after the beginning of trial </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Depression as assessed using Beck Questionaire  </outcome>
      <timepoint>Baseline, and at 4 weeks after the beginning of intervention </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as assessed using SF-36 Questionaire</outcome>
      <timepoint>Baseline, and 2 months after the beginning of intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1- Functional Dyspepsia (FD) patients according to Rome III criteria, based on general exam and gastrointestinal endoscopy
2- Normal range of lab data (CBC, LFT, Stool exam)   </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1- Steatorrhoea 2- Celiac disease 3- Night Diarrhea 4- Beginning of FD after the age of 40 years 5- Cancer (any form) 6- Liver disease 7- Pulmonary disease 8- Auto-immune disease 9- Psychiatry disease 10- pregnancy 11- Lactation 12- Irritable Bowl Syndrome (IBS) 13- History of Abdominal Surgery 14- Treatment with Lactolose or similar drugs 15- Consumption of drugs contributed to FD simultaneously 16- Consumption of Analgesic or Narcotic drugs       </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/06/2013</anticipatedstartdate>
    <actualstartdate>1/06/2013</actualstartdate>
    <anticipatedenddate>31/12/2013</anticipatedenddate>
    <actualenddate>16/10/2013</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Fars</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shahid Beheshti University of Medical Science</primarysponsorname>
    <primarysponsoraddress>Tehran State,
Tehran, 
Velenjak Str. , Shahid Chamran Highway,
Postcode: 1985717443</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti University of Medical Science</fundingname>
      <fundingaddress>Tehran State,
Tehran, 
Velenjak Str. , Shahid Chamran Highway,
Postcode: 1985717443</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Functional Dyspepsia (FD) is a widespread disease in community. The pathophysiology of Fd is not clearly evident, yet. The disease has a huge expense for health system and the treatments aren't sufficient unfortunately. 
Traditional Persian Medicine originated from the knowledge of great physicians like Avicenna, presented herbal drugs which have been used by people for hundreds years.  
An inexpensive accessible Persian herbal syrup named as Jollab has been introduced in Traditional Persian Medicine books repeatedly.
The aim of this study is to evaluate the efficacy of Jollab in relieveing symptoms of FD.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Shahid Beheshti University of Medical Science Ethics Committee</ethicname>
      <ethicaddress>Tehran State,
Tehran, 
Velenjak Str. , Shahid Chamran Highway,
Postcode: 1985717443</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mehdi Pasalar</name>
      <address>Postal Code:71888-37187
no. 2
Nikan Building,
Lane 21/2,
Mirzay-e-Shirazi Bulvard,
Shiraz
Shiraz University of Medical Sciences</address>
      <phone>+989173121345</phone>
      <fax />
      <email>pasalar@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mehdi Pasalar</name>
      <address>Postal Code:71888-37187
no. 2
Nikan Building,
Lane 21/2,
Mirzay-e-Shirazi Bulvard,
Shiraz
Shiraz University of Medical Sciences</address>
      <phone>+989173121345</phone>
      <fax />
      <email>pasalar@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Kamran Bagheri Lankarani</name>
      <address>Shiraz University of Medical Sciences,
Health policy Research Center, Building No 2, Eighth Floor, School of Medicine, Zand Avenue, Shiraz, Iran, Postal code: 7134853185</address>
      <phone>+987112309615</phone>
      <fax />
      <email>lankaran@sums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>